EUVIMEDEUVIMED entdecken
Crossref

Ligand‐Tethered Extracellular Vesicles Mediated RNA Therapy for Liver Fibrosis

Yue Liu, Shang Chen, Haoyan Huang, Adam C Midgley, Zhibo Han, Zhong-Chao Han, Qiong Li, Zongjin Li iD

Advanced Healthcare Materials · 2025

DOI: 10.1002/adhm.202403068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Yue Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Nankai University, 94 Weijin Road, Tianjin, 300071, China. Hauptthemen laut MEDLINE: Extracellular Vesicles, Liver Cirrhosis, MicroRNAs. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, Tianjin Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver fibrosis poses a significant global health burden, in which hepatic stellate cells (HSCs) play a crucial role. Targeted nanomedicine delivery systems directed at HSCs have shown immense potential in the treatment of liver fibrosis. Herein, a bioinspired material, engineered therapeutic miR‐181a‐5p (a miRNA known to inhibit fibrotic signaling pathways) and targeted moiety hyaluronic acid (HA) co‐functionalized extracellular vesicles (EVs) are developed. HA is incorporated onto the surface of EVs using DSPE‐PEG as a linker, allowing preferential binding to CD44 receptors, which are overexpressed on activated HSCs. Our results confirmed enhanced cellular uptake and improved payload delivery, as evidenced by the increased intracellular abundance of miR‐181a‐5p in activated HSCs and fibrotic livers. HA‐equipped EVs loaded with miR‐181a‐5p (DPH‐EVs@miR) significantly reduce HSC activation and extracellular matrix (ECM) deposition by inhibiting the TGF‐β/Smad signaling pathway, thus alleviating the progression of liver fibrosis. Additionally, DPH‐EVs@miR improves liver function, ameliorates inflammatory infiltration, and mitigates hepatocyte apoptosis, demonstrating superior hepatic protective effects. Collectively, this study reports a prospective nanovesicle therapeutic platform loaded with therapeutic miRNA and targeting motifs for liver fibrosis. The biomarker‐guided EV‐engineering technology utilized in this study provides a promising tool for nanomedicine and precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesLiver CirrhosisMicroRNAsAnimalsHepatic Stellate CellsHyaluronic AcidMiceMaleHumansLigandsSignal Transduction

Stichwörter der Autor:innen

RNA therapyextracellular vesicles (EVs)hepatic stellate cells (HSCs)hyaluronic acid (HA)liver fibrosis

Substanzen

MicroRNAsHyaluronic AcidLigands

Autor:innen und Institutionen

  • School of Medicine, Nankai University, 94 Weijin Road, Tianjin, 300071, China.
  • Key Laboratory of Bioactive Materials, Ministry of Education, College of Life Sciences, Nankai University, 94 Weijin Road, Tianjin, 300071, China.
  • Tianjin Key Laboratory of Engineering Technologies for Cell Pharmaceutical, National Engineering Research Center of Cell Products, AmCellGene Co. Ltd., 80 4th Street, TEDA, Tianjin, 300457, China.
  • Beijing Engineering Laboratory of Perinatal Stem Cells, Beijing Institute of Health and Stem Cells, Health Biotech Co. Ltd., No. 1 Kangding Road, Daxing, Beijing, 100176, China.
  • Henan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, 601 Jinsui Road, Xinxiang, 453003, China.
  • Henan Key Laboratory of Cardiac Remodeling and Transplantation, Zhengzhou Seventh People's Hospital, 17 Jingnan 5th Road, Zhengzhou, 450016, China.

ORCID-Profile: Zongjin Li

Förderung

  • National Natural Science Foundation of China
  • National Key R&D Program of China
  • Tianjin Natural Science Foundation
  • Open funding from Nankai University Eye Institute
  • National Key Research and Development Program of China
  • Natural Science Foundation of Tianjin Municipality

Zitieren

APA

Liu, Y., Chen, S., Huang, H., Midgley, A. C., Han, Z., Han, Z. C., Li, Q., & Li, Z. (2025). Ligand‐Tethered Extracellular Vesicles Mediated RNA Therapy for Liver Fibrosis. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202403068

Vancouver

Liu Y, Chen S, Huang H, Midgley AC, Han Z, Han ZC, et al. Ligand‐Tethered Extracellular Vesicles Mediated RNA Therapy for Liver Fibrosis. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202403068

BibTeX
@article{Liu2025,
  author = {Liu, Yue and Chen, Shang and Huang, Haoyan and Midgley, Adam C and Han, Zhibo and Han, Zhong-Chao and Li, Qiong and Li, Zongjin},
  title = {Ligand‐Tethered Extracellular Vesicles Mediated RNA Therapy for Liver Fibrosis},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  doi = {10.1002/adhm.202403068}
}
Kostenlos starten →